Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
39 hedge funds and large institutions have $182M invested in Verona Pharma in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 7 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.15% less ownership
Funds ownership: 7.69% → 7.55% (-0.15%)
7% less funds holding
Funds holding: 42 → 39 (-3)
27% less capital invested
Capital invested by funds: $248M → $182M (-$66.3M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.15M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.04M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.03M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$76.5K |
| 5 |
Millennium Management
New York
|
+$63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.13M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$785K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$82K |
| 4 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$80K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.4K |
VRNA Hedge Fund Activity: Q1 2022 in Review
39 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2022, worth a combined $182M — down 27% from $248M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VRNA and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Citigroup, opening a new position worth an estimated $2.15M. The largest seller was Wellington Management Group, cutting an estimated $6.13M.
- 39 institutional investors held Verona Pharma (VRNA) as of Q1 2022, down from 42 in Q4 2021.
- Funds reported $182M of Verona Pharma stock for Q1 2022, down 27% quarter-over-quarter.
- 4 funds opened new Verona Pharma positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest Verona Pharma buyer in Q1 2022 was Citigroup, an estimated $2.15M added.
- The largest Verona Pharma seller in Q1 2022 was Wellington Management Group, an estimated $6.13M sold.
Based on aggregated 13F filings for Q1 2022.